Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poseida Therapeutics (PSTX)
NASDAQ:PSTX
Poseida Therapeutics (PSTX) Stock Price & Analysis
432 Followers
PSTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.58 - $4.27
Previous Close$3.01
Volume457.04K
Average Volume (3M)531.11K
Market Cap
$291.84M
Enterprise Value$177.76M
Total Cash (Recent Filing)$198.65M
Total Debt (Recent Filing)$84.56M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 08, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding96,957,650
10 Day Avg. Volume365,162
30 Day Avg. Volume531,107
Standard Deviation0.20
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.75
Price to Sales (P/S)9.58
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit2.75
Enterprise Value/Ebitda-2.61
Forecast
1Y Price Target
$14.00Price Target Upside363.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Poseida Therapeutics News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $10 (or More), Say Analysts
PremiumCompany Announcements
Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive P-KLKB1-101 NHP data at ASGCT.
Financial PerformancePoseida had cash and cash equivalents of approximately $199M and expects to receive a $50M upfront payment from Astellas as well as a $15M milestone payment from Roche.
Research CollaborationPoseida announced a second partnership with Astellas Pharma focused on developing novel off-the-shelf cell therapies for solid tumors.
Bears Say
Clinical OutcomeOne patient passed away less than 60 days after therapy due to unrelated events, complicating the interpretation of treatment effectiveness.
Strategic DecisionThe company’s decision to no longer pursue its hybrid delivery candidates will delay its time to the clinic.
Treatment EfficacyA patient who achieved a very good partial response after P-BCMA-ALLO1 treatment progressed approximately 80 days after treatment.
---
Ownership Overview
39.77% Insiders
16.92% Mutual Funds
25.59% Other Institutional Investors
17.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTX FAQ
What was Poseida Therapeutics’s price range in the past 12 months?
Poseida Therapeutics lowest stock price was $1.58 and its highest was $4.27 in the past 12 months.
What is Poseida Therapeutics’s market cap?
Currently, no data Available
When is Poseida Therapeutics’s upcoming earnings report date?
Poseida Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Poseida Therapeutics’s earnings last quarter?
Poseida Therapeutics released its earnings results on May 14, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.17.
Is Poseida Therapeutics overvalued?
According to Wall Street analysts Poseida Therapeutics’s price is currently Undervalued.
Does Poseida Therapeutics pay dividends?
Poseida Therapeutics does not currently pay dividends.
What is Poseida Therapeutics’s EPS estimate?
Poseida Therapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Poseida Therapeutics have?
Poseida Therapeutics has 96,957,650 shares outstanding.
What happened to Poseida Therapeutics’s price movement after its last earnings report?
Poseida Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went up 18.493%.
Which hedge fund is a major shareholder of Poseida Therapeutics?
Among the largest hedge funds holding Poseida Therapeutics’s share is Aisling Capital Management LP. It holds Poseida Therapeutics’s shares valued at 3M.
---
Poseida Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (363.58% Upside)
$14.00 (363.58% Upside)
Blogger Sentiment
Bullish
PSTX Sentiment 75%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 45.6%
Last 30 Days ▲ 45.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
71.02%
12-Months-Change
Fundamentals
Return on Equity
-89.91%
Trailing 12-Months
Asset Growth
-16.27%
Trailing 12-Months
Company Description
Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
---
PSTX Stock 12 Month Forecast
Average Price Target
$14.00
▲(363.58% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Adverum Biotechnologies
―
Cellectis SA
―
Sangamo Biosciences
―
Best Analysts Covering PSTX
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+5.92%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +5.92% per trade.
---